Fate Therapeutics
FATE
46 hedge funds and large institutions have $28.4M invested in Fate Therapeutics in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 12 closing their positions.
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
15% less funds holding
Funds holding: 54 → 46 (-8)
55% less capital invested
Capital invested by funds: $62.7M → $28.4M (-$34.3M)
67% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 12
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BGA
Belmont Global Advisors
Dallas,
Texas
|
+$653K |
| 2 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
+$515K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$454K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$344K |
| 5 |
Goldman Sachs
New York
|
+$303K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.4M |
| 2 |
BC
Broadfin Capital
New York
|
-$3.75M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$1.82M |
| 4 |
KCM
Kingdon Capital Management
New York
|
-$697K |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$569K |
FATE Hedge Fund Activity: Q1 2016 in Review
46 of the 3,767 institutional investors tracked by Wall St. Rank reported a position in Fate Therapeutics (FATE) for Q1 2016, worth a combined $28.4M — down 55% from $62.7M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of FATE and 4 opened new positions — a net loss of 8 holders — while 13 trimmed existing stakes and 19 added.
The largest buyer was Belmont Global Advisors, adding an estimated $653K. The largest seller was Wellington Management Group, exiting entirely with an estimated $4.4M sold.
- 46 institutional investors held Fate Therapeutics (FATE) as of Q1 2016, down from 54 in Q4 2015.
- Funds reported $28.4M of Fate Therapeutics stock for Q1 2016, down 55% quarter-over-quarter.
- 4 funds opened new Fate Therapeutics positions in Q1 2016 and 12 closed out, a net change of -8 holders.
- The largest Fate Therapeutics buyer in Q1 2016 was Belmont Global Advisors, an estimated $653K added.
- The largest Fate Therapeutics seller in Q1 2016 was Wellington Management Group, an estimated $4.4M sold.
Based on aggregated 13F filings for Q1 2016.